Integra LifeSciences Holdings Corporation $IART Shares Purchased by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY raised its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 50.6% during the 1st quarter, Holdings Channel reports. The firm owned 4,012,698 shares of the life sciences company’s stock after purchasing an additional 1,347,700 shares during the quarter. Integra LifeSciences comprises 1.4% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 19th biggest holding. Paradigm Capital Management Inc. NY owned about 0.05% of Integra LifeSciences worth $37,800,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $25,000. Osaic Holdings Inc. raised its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the last quarter. GAMMA Investing LLC lifted its stake in Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after buying an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Integra LifeSciences during the 4th quarter valued at $124,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Citigroup reissued a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective for the company. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Trading Up 6.6%

Shares of IART stock opened at $19.79 on Friday. The firm’s 50-day simple moving average is $17.39 and its 200-day simple moving average is $13.31. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. Integra LifeSciences Holdings Corporation has a 1-year low of $8.70 and a 1-year high of $20.26. The firm has a market cap of $1.54 billion, a P/E ratio of -3.06, a PEG ratio of 1.29 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.